Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751647 | 0.81 | HDAC6 (0.31) | EPHX2CYP2C9CYP2C19CYP2J2P2RX7 | |
| SCHEMBL5751657 | 0.76 | CTSS (0.38) | EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL5755139 | 0.72 | P2RX7 (0.35) | EPHX2CYP2C9CYP2C19CYP2J2P2RX7 | |
| SCHEMBL5749682 | 0.72 | PPARG (0.44) | EPHX2L3MBTL1 | |
| SCHEMBL5751624 | 0.72 | PPARG (0.44) | EPHX2L3MBTL1 | |
| SCHEMBL5751323 | 0.72 | GRM8 (0.36) | P2RX7 | |
| SCHEMBL5752733 | 0.72 | KMT2A (0.48) | CYP2C9 | |
| SCHEMBL9135960 | 0.70 | RAB9A (0.44) | EPHX2CYP2C9CYP2C19CYP2J2L3MBTL1 | |
| SCHEMBL5753316 | 0.70 | PPARG (0.45) | EPHX2 | |
| SCHEMBL5752432 | 0.69 | MEN1 (0.44) | CYP2C9CYP2C19PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | EPHX2 1434/4885CYP2C9 1548/4885CYP2C19 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.